MCM 2 is targeted by lovastatin in NSCLC cells. This inhibition led to cellular cycle block, inhibiting cyclin D1, CDK4 and Rb, but increasing p21 and p53 expression [47]. Here, CDKN1A is linked to non-small cell lung carcinoma.